Acesso livre
Acesso livre

Medicina de Emergências

Estudo multicêntrico de coorte histórica | Gasometria arterial: é tão segura quanto se acredita?

8 Mar, 2022 | 17:07h

Arterial blood gas analysis: as safe as we think? A multicentre historical cohort study – ERJ Open

[Preprint] Estudo RECOVERY mostra que baricitinibe reduz mortes em pacientes internados com COVID-19.

8 Mar, 2022 | 16:22h

Comunicado de imprensa: RECOVERY trial shows Baricitinib reduces deaths in patients hospitalised with COVID-19 – University of Oxford

Estudo original: Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

Comentários:

Arthritis drug reduces mortality in severe COVID-19, huge clinical trial finds – Science

Covid-19: Anti-inflammatory treatment baricitinib reduces deaths in patients admitted to hospital, finds trial – The BMJ

Another life-saving Covid drug identified – BBC

Conteúdos relacionados:

WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.

RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19.

Randomized trial: Baricitinib plus remdesivir reduce recovery time in patients with COVID-19

 

Comentário do autor no Twitter (fio – clique para saber mais)

 

Diretriz atualizada da OMS recomenda condicionalmente o molnupiravir para pacientes com Covid-19 não grave sob alto risco de internação.

8 Mar, 2022 | 16:14h

Comunicado de imprensa BMJ: WHO recommends antiviral drug for patients with non-severe covid-19 at highest risk of hospital admission – BMJ

Comunicado de imprensa OMS: WHO updates its treatment guidelines to include molnupiravir

Ver diretriz atualizada: A living WHO guideline on drugs for covid-19 – BMJ

Conteúdos relacionados:

Editorial (recém-publicado): Molnupiravir’s authorisation was premature – The BMJ

RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Estudo pré-pós intervenção | A introdução de um sistema de alerta por mensagem de texto para avisar voluntários próximos a pacientes com parada cardíaca em casa foi associada a maior chance de sobrevida e alta hospitalar.

8 Mar, 2022 | 16:04h

Alert system-supported lay defibrillation and basic life-support for cardiac arrest at home – European Heart Journal

Editorial: Volunteer first responders for out-of-hospital cardiac arrest at home: the missing link for improved survival? – European Heart Journal

 

Comentário no Twitter

 

Estudo randomizado | Aspirina e heparina não fracionada aumentam o risco de hemorragia intracraniana sintomática em pacientes submetidos a tratamento endovascular de AVC isquêmico.

3 Mar, 2022 | 16:50h

Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial – The Lancet (link para o resumo – $ para o texto completo)

M-A | Uso de tocilizumabe e sarilumabe isoladamente ou em combinação com corticosteroides para Covid-19.

3 Mar, 2022 | 16:44h

Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis – BMJ Medicine

Editorial: Treatment of severe covid-19 with interleukin 6 receptor inhibition – BMJ Medicine

Estudo relacionado (publicado recentemente): Mortality Rates Among Hospitalized Patients With COVID-19 Infection Treated With Tocilizumab and Corticosteroids: A Bayesian Reanalysis of a Previous Meta-analysis – JAMA Network Open

Estudo observacional sugere que a norepinefrina é uma opção melhor do que a epinefrina em pacientes com parada cardíaca e choque pós-ressuscitação.

3 Mar, 2022 | 16:29h

Epinephrine versus norepinephrine in cardiac arrest patients with post-resuscitation shock – Intensive Care Medicine (link para o resumo – $ para o texto completo)

Conteúdo relacionado: Randomized Trial: Epinephrine vs Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction

 

 

M-A | Associação da administração de ácido tranexâmico com mortalidade e eventos tromboembólicos em pacientes com lesão traumática.

3 Mar, 2022 | 15:24h

Association of Tranexamic Acid Administration With Mortality and Thromboembolic Events in Patients With Traumatic Injury: A Systematic Review and Meta-analysis – JAMA Network Open

Conteúdos relacionados:

M-A: Prehospital Tranexamic Acid reduces mortality among bleeding trauma patients without increasing the risk of venous thromboembolism.

Tranexamic acid after traumatic brain injury: Exploratory analysis combining data from CRASH-2 and CRASH-3 trials suggests reduced mortality

Meta-analysis: Efficacy and safety of tranexamic acid in acute traumatic brain injury

Randomized trial: Tranexamic acid during prehospital transport in patients at risk for hemorrhage after injury

Randomized trial: Out-of-hospital tranexamic acid does not improve neurologic outcomes in patients with traumatic brain injury

Editorial: Is Tranexamic Acid Going to CRASH the Management of Traumatic Brain Injury?

Practice-Changing: Tranexamic Acid Reduces the Risk of Head Injury-related Death in Patients with Mild-to-moderate Head Injury

Estudo randomizado por cluster | Em adultos com parada cardíaca fora do hospital, a colocação de um dispositivo para via aérea supraglótico resultou em taxas similares de retorno da circulação espontânea em comparação à entubação orotraqueal.

2 Mar, 2022 | 11:45h

Effect of Placement of a Supraglottic Airway Device vs Endotracheal Intubation on Return of Spontaneous Circulation in Adults With Out-of-Hospital Cardiac Arrest in Taipei, Taiwan: A Cluster Randomized Clinical Trial – JAMA Network Open

Comentário: Cardiac Arrest Patients Don’t Necessarily Do Better With Intubation— Debate on prehospital advanced airway management continues – MedPage Today (necessário cadastro gratuito)

 

Comentário no Twitter

 

Revisão JACC | Anticoagulação em pacientes com COVID-19.

2 Mar, 2022 | 11:42h

Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week – Journal of the American College of Cardiology

Comentário: Review of Anticoagulation in Patients With COVID-19: Key Points – American College of Cardiology

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.